Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

BioInvent International

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Biological: TB-403

Study type: Interventional

Funder types: Industry

Identifiers

NCT00702494

07-TB-403-02

EUDRACT No: 2008-001345-25

Details and patient eligibility

About

TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented.

In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Enrollment: 21 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed malignity
• Measurable disease
• Performance status 1 or less (ECOG)

Exclusion criteria

• Acute illness or infection
• Concurrent second malignancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

1

Experimental group

Description:

Multiple IV doses of TB-403, an antibody directed against PlGF

Treatment:

Biological: TB-403